Tirzepatide Recall: Houston Rx 2mL vial (40 MG per vial)
Announced 2026-10-21 · FDA
The FDA recall concerns Tirzepatide/Niacinamide 2mL vials distributed nationwide in the USA by Houston Rx LLC due to lack of assurance of sterility. Lot TZN-080326-20/2-2 and Beyond Use Date 12/01/2026 are cited. No corrective action is specified in the information provided.
| Brand | Houston Rx LLC |
|---|---|
| Product | Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032. |
| Reason | Lack of assurance of sterility. |
| Severity | moderate |
| Units affected | 7 |
| Distribution | Nationwide in the USA. |
| Agency | FDA |
WHAT YOU SHOULD DO
- Check your inventory for Lot TZN-080326-20/2-2 and the Beyond Use Date 12/01/2026.
- Do not use any affected vials.
- Contact your healthcare provider or Houston Rx LLC for return or disposal instructions.
- If you have used the product and have concerns, report them to a clinician or FDA MedWatch.
How to identify the recalled item
| Lot / date codes | Lot# TZN-080326-20/2-2, Beyond Use Date: 12/01/2026. |
|---|---|
| Lot / date codes | Lot# SER-081726-1-10, Beyond Use Date: 10/01/2026. |
These are the identifiers FDA published for this recall. Most recall notices list no UPC or model number at all — if the code on your item is not shown here, that does not mean the item is excluded. Check the official notice, or contact the company.
This is an automatically maintained record of an official recall notice. Details can change; always follow the official notice linked above. See all records in the Recall Database.